CME provided by Research to Practice. This symposium is supported by AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck, and TESARO, a GSK Company.
Neil Love, MD, Research to Practice, Miami, FL
Robert L. Coleman, MD, FACOG, FACS, The University of Texas MD Anderson Cancer Center, Houston, TX
Kathleen Moore, MD, The University of Oklahoma, Oklahoma City, OK
Ignace Vergote, MD, PhD, Cancer Institute at University Hospitals, Leuven, Belgium
Additional faculty to be announced.
This CME symposium will focus on the burgeoning role of PARP inhibition in the management of ovarian cancer (OC). Research To Practice (RTP) president and medical oncologist Dr. Neil Love will moderate the program, and four clinical investigators will serve as the faculty. Leading up to SGO, RTP will recruit 21 additional medical and gynecologic oncology investigators who, along with the faculty, will participate in a unique educational survey designed to illuminate their general practice patterns regarding the protocol and nonprotocol role of PARP inhibitors in the treatment of patients with OC. RTP will aggregate the results of the assessment and prioritize key data points for presentation during the program. The activity will be divided into four distinct modules, each featuring graphical displays of the investigator survey results and a faculty member-led review of relevant research and ongoing clinical trials. To make the program more interactive and relevant to those in the room, clinician attendees will use networked iPads to complete a similar survey, the results of which will be juxtaposed with those of the investigators to illuminate knowledge and practice gaps among the community practitioners. Attendees will also be encouraged to use the iPads to submit their own questions and cases to the faculty. Dr. Love will intersperse select inquiries throughout the discussions to foster additional conversation and ensure that a variety of perspectives emerge.